Seattle, WA -- (SBWIRE) -- 03/04/2020 -- Cell therapy is the administration of living cells in patients for the treatment of a disease. The source of cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for treatment of a disease. Moreover, it modifies the expression of an individual's genes or repair abnormal genes. The therapy involves administration of nucleic acid (DNA/RNA) with carriers called as vectors.
Increasing prevalence of cancer diseases is a major factor driving the Cell and Gene Therapy market growth. According to the World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, introduction of innovative products and rich pipeline of cell and gene therapy is expected to boost the market growth. For instance, around 150 gene therapies are currently in the development stage. Gene replacement accounts for around two third of gene therapy pipeline. However, around 49% of gene therapies are under preclinical and discovery stages. During 2012-18, around 351 gene therapy deals were signed. For instance Gilead's Kite Pharma received exclusive rights to Sangamo Therapeutics' zinc finger nuclease gene editing technology, for $3.2bn.
Request a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2475
Key players in the market are focused on launching novel cell and gene therapies, in order to treat various diseases and address the critical unmet needs of patients. For instance, in June 2011, Fibrocell Technologies, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Azficel-T, which can be used for the treatment of nasolabial fold wrinkles.
Moreover, in November 2011, New York Blood Center, Inc. received approval from FDA for Hemacord. It is indicated for unrelated donor hematopoietic progenitor cell transplantation procedures and in patients with disorders affecting the hematopoietic system that are inherited, acquired, or results from myeloablative treatment in children. In October 2017, Kite Pharma received approval from the U.S. FDA for Yescarta (axicabtagene ciloleucel), which is used for the treatment of adults with large B-cell lymphoma. It was the first chimeric antigen receptor (CAR) T-cell therapy to receive FDA approval for large B-cell lymphoma.
Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in June 2017, Johnson & Johnson acquired Actelion Ltd. Moreover, in October 2017, Gilead Sciences acquired Kite Pharma. Kite Pharma is involved in developing chimeric antigen receptor T-cell therapy, to recognize and attack malignant cells.
The global cell and gene therapy market is expected to exhibit a CAGR of 21.9% over the forecast period, owing to increasing prevalence of cardiovascular diseases, cancer, and neurological disorders
Among therapy type, the gene therapy segment held a dominant position in the cell and gene therapy market in 2018. For instance, in November 2018, Pharma Intelligence Company estimated that around 55% of the pipeline is of gene therapy, majorly medicines that are delivered by in vivo.
Global Cell and Gene Therapy Market, By Therapy Type:
Global Cell and Gene Therapy Market, By Indication:
Global Cell and Gene Therapy Market, By Scale of Operation:
Bristol-Myers Squibb Company
Regeneron Pharmaceuticals and Sanofi
Kolon TissueGene, Inc.
JCR Pharmaceuticals Co., Ltd.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2475
About Coherent Insights
Coherent Insights is a prominent research and consulting firm offering action-ready syndicated research reports, custom analysis, consulting services, and competitive analysis through various recommendations related to emerging trends, technologies, and potential absolute dollar opportunity.
Other Related Research Reports:
Name: Mr. Shah
Phone: US +12067016702
Country: United States